{"nctId":"NCT00075829","briefTitle":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","startDateStruct":{"date":"2003-12"},"conditions":["Multiple Myeloma"],"count":710,"armGroups":[{"label":"Auto transplants plus Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: One Autologous Transplant","Procedure: Second Autologous Transplant","Drug: Thalidomide","Drug: Dexamethasone"]},{"label":"Auto transplants","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: One Autologous Transplant","Procedure: Second Autologous Transplant","Behavioral: Observation"]},{"label":"Auto and Allo transplants","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: One Autologous Transplant","Procedure: Non-Myeloablative Allogeneic Transplant","Behavioral: Observation"]}],"interventions":[{"name":"One Autologous Transplant","otherNames":[]},{"name":"Non-Myeloablative Allogeneic Transplant","otherNames":[]},{"name":"Second Autologous Transplant","otherNames":[]},{"name":"Thalidomide","otherNames":["Thalomidâ„¢"]},{"name":"Dexamethasone","otherNames":["Decadron, DexPak"]},{"name":"Observation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meeting the Durie and Salmon criteria for initial diagnosis of MM\n* Stage II or III MM at diagnosis or anytime thereafter\n* Symptomatic MM requiring treatment at diagnosis or anytime thereafter\n* Received at least three cycles of initial systemic therapy and are within 2-10 months of initiation of the initial therapy (this time frame excludes the time for mobilization therapy)\n* If receiving chemotherapy-based mobilization regimens, must be able to receive high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy whether delivered at the transplant center or at a referring center\n* Adequate organ function as measured by:\n\n  1. Cardiac: Left ventricular ejection fraction at rest greater than 40%\n  2. Hepatic: Bilirubin less than 2 times the upper limit of normal and alanine transaminase (ALT) and aspartate transaminase (AST) less than 3 times the upper limit of normal\n  3. Renal: Creatinine clearance greater than 40 ml/min (measured or calculated/estimated)\n  4. Pulmonary: Carbon monoxide diffusion (DLCO), Volume forcibly exhaled in one second (FEV1), and Forced Vital Capacity (FVC) greater than 50% of predicted value (corrected for hemoglobin), or O2 saturation greater than 92% of room air\n* An adequate autologous graft defined as a cryopreserved PBSC graft containing at least 4.0 x 106 CD34+ cells/kg patient weight; if prior to enrollment it is known that a patient will be on the auto-allo arm (i.e., a consenting, eligible HLA-matched sibling donor is available), the required autograft must contain at least 2.0 x 10\\^6 CD34+ cells/kg patient weight; the graft may not be CD34+ selected or otherwise manipulated to remove tumor or other cells; the graft can be collected at the transplanting institution or by a referring center; for patients without an HLA-matched sibling donor, the autograft must be stored so that there are two products each containing at least 2 x 10\\^6 CD34+ cells/kg patient weight\n\nExclusion Criteria:\n\n* Never advanced beyond Stage I MM since diagnosis\n* Non-secretory MM (absence of a monoclonal protein \\[M protein\\] in serum as measured by electrophoresis and immunofixation and the absence of Bence Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques)\n* Plasma cell leukemia\n* Karnofsky performance score less than 70%, unless approved by the Medical Monitor or one of the Protocol Chairs\n* Uncontrolled hypertension\n* Uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms)\n* Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Medical Monitor or one of the Protocol Chairs; cancer treated with curative intent more than 5 years previously will be allowed\n* Pregnant or breastfeeding\n* Seropositive for the human immunodeficiency virus (HIV)\n* Unwilling to use contraceptive techniques during and for 12 months following treatment\n* Prior allograft or prior autograft\n* Received mid-intensity melphalan (more than 50 mg IV) as part of prior therapy\n* Prior organ transplant requiring immunosuppressive therapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"Patients are considered a failure for this endpoint if they die or if they progress or relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) for Standard Risk","description":"The event is death from any cause, patients alive at the time of last observation are considered censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) for High Risk","description":"The event is death from any cause, patients alive at the time of last observation are considered censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Progression/Relapse","description":"Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Treatment Related Mortality (TRM)","description":"TRM is defined as death occurring in a patient from causes other than relapse or progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Interval From First to Second Transplantation","description":"Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"101","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidences of Graft Versus Host Disease (GVHD)","description":"Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidences of Chronic GVHD","description":"Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":436},"commonTop":["Thrombocytopenia","Angiosarcoma"]}}}